Posts By Alex
479Wire StoriesNidec Announces Differences between Projected and Actual Financial Results for First-Half FY2023
KYOTO, Japan–(BUSINESS WIRE)–Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) (the “Companyâ€) today announced differences between its financial forecast for the six months...
- 662Wire Stories
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
Approval based on DESTINY-Lung02 trial results where Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a confirmed objective response rate of 49.0% and median...
- 529Wire Stories
Bias in AI Computer Vision Systems Dramatically Reduced with Synthetic Data ‘Digital Humans’
Mindtech’s Digital DNA technology creates a diverse range of Digital Humans that allow for statistically fair representation of the eight billion real...
- 487Wire Stories
APO’s Newest Member Turkiye Hosts 64th Workshop Meeting of Heads of National Productivity Organizations
ANKARA, Turkiye–(BUSINESS WIRE)–#APO–Turkiye, the Asian Productivity Organization’s (APO’s) newest member, generously hosted the 64th Workshop Meeting (WSM) of Heads of National Productivity...
- 496Wire Stories
Covation Holdings Continues Expansion in Asia Pacific With New Regional Corporate Headquarters
HONG KONG–(BUSINESS WIRE)–Covation Holdings Limited, the global manufacturer of multiple wheeled goods brands, today announced the addition of a new global corporate...
- 496Wire Stories
Berkshire Hathaway Specialty Insurance Names Sami Jaghbir as Underwriting Manager in Queensland
BRISBANE, Australia & BOSTON–(BUSINESS WIRE)–Berkshire Hathaway Specialty Insurance (BHSI) today announced that it has appointed Sami Jaghbir as Underwriting Manager, Queensland. “Sami...
- 581Wire Stories
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy – – Enfortumab...
- 492Wire Stories
Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial
Encouraging overall response rate of 46% and disease control rate of 98% with a median duration of response of 11.2 months seen...
- 622Wire Stories
Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab showed a confirmed objective response rate of 79% Two ongoing phase 3 trials are...
- 568Wire Stories
CHNT Group Showed at The 24th Conference on The Electric Power Supply Industry
XIAMEN, China–(BUSINESS WIRE)–On October 20th, the 24th Conference on The Electric Power Supply Industry kicked off in Xiamen, attended by more than...
